Select region

Press release Göteborg 2016-01-14

Getinge announces date of 2015 Q4 report and conference call

Getinge will issue its Q4 report for 2015 on Thursday January 28th 2016 at 13:00 CET, followed by a conference call at 15:00 CET, hosted by Alex Myers, CEO, and Ulf Grunander, CFO.

We invite fund managers, analysts and the media to participate in the conference call. Please see below details to join the conference:

Swedish dial in number: +46 (0)8 5065 3937

UK dial in number: +44 (0)20 3427 1914

US dial in number: +1 212 444 0896

Participant passcode: 9475750


14:45 Call in to the conference

15:00 Review of the Q4 report

15:20 Q&A

16:00 End of conference

Two hours after the end of the conference call, a recorded version of the conference can be accessed for 5 working days on the following number:

Sweden: +46 (0)8 5051 3897

UK: +44 (0)20 3427 0598

US: +1 347 366 9565

Code: 9475750

During the telephone conference a presentation will be held. To access the presentation, please use this link:

Alternatively enter the Live Meeting site and log into your meeting using the Meeting ID and Password below:

Live Meeting:

Your Name: (Enter your name)

Web Meeting ID: 9475750

Web Meeting Password: pw1095

For more information, please contact:
Kornelia Rasmussen, Executive Vice President Communications & Brand Management
Phone: +46 (0)10 335 5810

Getinge Group is a leading global provider of innovative solutions for operating rooms, intensive-care units, hospital wards, sterilization departments, elderly care and for life science companies and institutions. With a genuine passion for life we build quality and safety into every system. Our unique value proposition mirrors the continuum of care, enhancing efficiency throughout the clinical pathway. Based on our first-hand experience and close partnerships, we are able to exceed expectations from customers – improving the every-day life for people, today and tomorrow.

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.